Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
ATLANTA, Oct. 25, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the third quarter ended September 30, 2017, after the close of the financial markets on Wednesday, November 1, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, November 2, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Thursday, November 2nd, 2017 9:00 AM ET
Conference dial-in: 877.269.7756
International dial-in: 201.689.7817
Conference Call Name: Alimera Sciences' Third Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in Alimera’s product and development portfolio designed to treat early and late stage diseases. For more information, please visit www.alimerasciences.com.
Contact
CG CAPITAL
Rich Cockrell
877.889.1972
[email protected]
